Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

115.23
+0.49000.43%
Pre-market: 116.891.66+1.44%04:04 EDT
Volume:910.31K
Turnover:105.35M
Market Cap:12.46B
PE:254.00
High:118.07
Open:114.80
Low:113.98
Close:114.74
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.97
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.65
PE(LYR):140.52

Loading ...

GUIDANCE: (CORT) Corcept Therapeutics Expects 2026 Revenue Range $950M-$1.05B, vs. FactSet Est of $899.5M

MT Newswires Live
·
May 01

Corcept Q1 turns to USD 31.8 million net loss; revenue rises to USD 164.9 million

Reuters
·
May 01

Corcept says Phase 2 ALS study shows 87% lower death risk with dazucorilant

Reuters
·
May 01

Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate

Benzinga Earnings
·
May 01

BRIEF-Corcept Therapeutics Q1 EPS USD -0.3

Reuters
·
May 01

Corcept Therapeutics Inc - Dazucorilant Shows 87% Reduction in Risk of Death Versus Placebo

THOMSON REUTERS
·
May 01

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 01

Corcept Therapeutics Outlook FY Revenue USD 950-1,050 Million

THOMSON REUTERS
·
May 01

Corcept Therapeutics Inc - Expects Return to Profitability in Q2 2026

THOMSON REUTERS
·
May 01

A Look At Corcept Therapeutics (CORT) Valuation After Lifyorli’s FDA Approval And Upcoming ROSELLA Phase 3 Data

Simply Wall St.
·
Apr 26

Corcept Therapeutics to report Q1 results, host conference call

Reuters
·
Apr 24

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

THOMSON REUTERS
·
Apr 24

Corcept to present Phase 3 ROSELLA Lifyorli ovarian cancer survival subgroup data at ASCO 2026

Reuters
·
Apr 22

Corcept Therapeutics announces annual shareholder meeting notice

Reuters
·
Apr 18

Corcept Therapeutics presents final overall survival data from ROSELLA trial

TIPRANKS
·
Apr 11

Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%

Reuters
·
Apr 11

Corcept Presents Complete Data From Pivotal Rosella Trial in Sgo Late-Breaker With Simultaneous Publication in the Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Apr 11

Corcept CDO William Guyer sells 20,000 shares for $819,400

Reuters
·
Apr 09

Corcept Faces Securities Lawsuits As Relacorilant Story Splits On FDA Outcomes

Simply Wall St.
·
Apr 03

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

TIPRANKS
·
Apr 02